RSV LID ΔM2-2 1030s

RSV LID ΔM2–2 1030s is a recombinant, live attenuated vaccine candidate designed to prevent infection by human respiratory syncytial virus (RSV). It is based on the subgroup A, strain A2 of RSV and incorporates several genetic modifications for attenuation and stability. Specifically, it features a deletion of the M2–2 gene (a regulatory protein involved in viral RNA synthesis), silencing of its translation initiation codons, additional deletions in the SH gene region for plasmid stability, and a genetically stabilized temperature-sensitivity mutation ("1030s") in the viral polymerase protein. The vaccine is administered intranasally as nose drops and has been evaluated primarily in seronegative infants and young children aged 6 to 24 months. Clinical studies have shown that it induces robust neutralizing antibody responses with good infectivity and no evidence of genetic instability. The vaccine was initially developed by the National Institute of Allergy & Infectious Diseases (NIAID) with manufacturing support from Charles River Laboratories; Sanofi Pasteur has also been involved as an active organization[1][3][5][6].

Other names

RSV LID ΔM2-2 1030sLID/ΔM2-2/1030s